The life science and biotech PR distribution service

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Minaris logo

  • With the recent FDA approval of LYFGENIA™, developed by bluebird bio, Minaris Regenerative Medicine North America is now supporting a commercial cell and gene therapy (CGT) product.
  • The first commercial drug product was manufactured in early May. This confirms the capability of Minaris Regenerative Medicine as a commercial manufacturing CDMO.

ALLENDALE, NJ, USA, May 08, 2024 / Biotech Newswire / -- Minaris Regenerative Medicine, a global manufacturing partner to the cell and gene therapy industry, today announced that the first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

The Allendale facility passed Food and Drug Administration (FDA) pre-Licensing inspections, underscoring the necessary capabilities and expertise to successfully manufacture cell and gene therapy for commercial use.

Minaris Regenerative Medicine has manufactured cell and gene therapy products for more than 20 years, supporting its partners from development stage to commercial phase.

Dr. Hiroto Bando, CEO, Minaris Regenerative Medicine, commented – “The commencement of commercial manufacturing for LYFGENIA represents an important step for the cell and gene therapy industry as it will allow many patients fighting sickle cell disease to benefit from this new, potentially curative medicine. Now, I am pleased to announce that Minaris Regenerative Medicine has commercial manufacturing experience in all three of our regions, Japan, Germany, and now the United States.”  


For high resolution please click the image.


About Minaris Regenerative Medicine
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. Our vision is creating future cell therapy miracles together and we are committed to providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society’s well-being. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 25 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Resonac Holdings Corporation.



Minaris Regenerative Medicine
Emmanuelle Bommier
Head of Sales and Marketing North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 (908) 720 2007


Keywords: Humans; Regenerative Medicine; United States Food and Drug Administration; Genetic Therapy; Anemia, Sickle Cell; North America; United States; Commercial manufacturing; Cell and gene therapy (CGT); FDA approval; LYFGENIA™; bluebird bio; Minaris Regenerative Medicine; Allendale, NJ; Sickle cell disease; Contract development and manufacturing organization (CDMO); Clinical and commercial manufacturing services

Source: Biotech Newswire

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.